Jan
16

why did jaguar health stock drop

 

Napo to host virtual workshop September 30 th about the GI consequences of HIV SAN FRANCISCO, CA / ACCESSWIRE / September 28, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's wholly owned subsidiary, Napo Pharmaceuticals, Inc. BioVeda China Fund ("BVCF"), a private equity and growth capital investor based in China, funded the initial closing and, SAN FRANCISCO Jan. 14, 2014 /PRNewswire/ -- An investigational new animal drug application (INADA) number has been received by Napo Pharmaceuticals, Inc. for its lead animal drug candidate, SP-303, which is isolated and purified from Croton lechleri, a medicinal plant sustainably harvested from the, Sustainability & Community Benefit Sharing, Jaguar Health Provides Replay Link & High-level Overview of January 14th Investor Webcast, Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher, Jaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq Rules, Jaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference, Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ COVID-19 Recovery Patients in Europe, Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera, Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream, Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar, REMINDER: Jaguar Health to Host Investor Call Thursday, December 17, 2020 to Allow Management to Review Developments Since the Definitive Proxy Statement for the Company’s December 9, 2020 Special Meeting of Stockholders Was Filed, Jaguar Health Announces Adjournment of Its Special Meeting of Stockholders Until Tuesday, December 22, 2020, Nasdaq's Listing and Hearing Review Council Stays Panel Determination Requiring Jaguar Health's Compliance with the Bid Price Requirement by December 23, 2020, Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Fifth Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020, Jaguar Health Announces Plan to Develop and Commercialize Crofelemer, the Company's Novel Proprietary Drug, for the Indication of Inflammatory Diarrhea, Initially in 'Long-Hauler' COVID-19 Recovery Patients, Jaguar Health Announces Release of Podcast Interview with The Wall Street Resource, Jaguar Health, Inc. Reports 2020 Third Quarter Financial Results, Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates, Jaguar Health Receives Positive Nasdaq Listing Determination, Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer", Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), Napo Pharmaceuticals, a Subsidiary of Jaguar Health, Launches Web-based NapoCares Platform to Enhance Patient Access to Mytesi, Jaguar Health and Its Subsidiary Bolster Management Team with Appointment of Melissa Yeager, J.D. Provides Second Quarter 2018 Financial Updates, Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product, Jaguar Health Appoints Pharmaceutical Industry Veteran David MacNaughtan to Board of Directors, Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors, Napo Pharmaceuticals Presents New Data at the 13th International Conference on HIV Treatment and Prevention Adherence Regarding the Use of Mytesi (Crofelemer) to Treat Noninfectious Diarrhea in HIV Patients, Jaguar Health, Inc. Results Reported at 9th International AIDS Society (IAS) Conference on HIV Science in Paris, France Over 7 Million Patients with HIV Worldwide May Benefit from the Reduction in Diarrhea Achieved with Long-Term Mytesi Therapy SAN FRANCISCO --(BUSINESS WIRE)--Jul. 6, 2017-- As previously announced, Jaguar Animal Health, Presentation will cover new data on the long-term efficacy of crofelemer (Mytesi®) based on a supplemental analysis of the ADVENT trial SAN FRANCISCO --(BUSINESS WIRE)--Jun. SAN FRANCISCO, CA / ACCESSWIRE / March 12, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), is hosting a Facebook Live conversation at 3 p.m. Transaction Proceeds Will be Allocated to Support Advancement of Regulatory Activities Associated with Jaguar's Pipeline, Including the Company's Lead Product Candidate, Crofelemer, for Cancer Therapy-related Diarrhea SAN FRANCISCO, CA / ACCESSWIRE / March 5, 2020 / Jaguar Health, Inc. SAN FRANCISCO, CA / ACCESSWIRE / February 20, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the nonprofit American Botanical Council (ABC) has given the 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to the Company's. Even worse, it's down 17% in about a month, which isn't fun at all. SAN FRANCISCO --(BUSINESS WIRE)--Jun. This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time . Jaguar Health Inc () Stock Market info Recommendations: Buy or sell Jaguar Health stock? Mytesi ® Novel Anti-Diarrheal Mechanism of Action Distinguished as Non-Opioid SAN FRANCISCO, CA / ACCESSWIRE / September 23, 2019 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued the following comments today regarding the September 20, 2019 announcement by the U.S. SAN FRANCISCO, CA / ACCESSWIRE / September 19, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Lisa Conte , Jaguar's founder, president and CEO, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 , at 8:30 a.m. Company's Legacy Animal Health Business Supports Focus on Human Health Benefits SAN FRANCISCO, CA / ACCESSWIRE / September 18, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued the following updates today regarding the Company's September 11, 2019, Puerto Rico Had the 7th Highest Cumulative Rate of HIV Infection in the Nation in 2016 SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the “Company”) announced today that the Drug and Pharmacy Division of the Government of Puerto Rico Health, SAN FRANCISCO, CA / ACCESSWIRE / September 9, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) announced today that the Company has promoted Jonathan Wolin , an accomplished healthcare and biotech executive, to the expanded role of chief of staff, chief compliance officer and. The Combined Company’s New Name is Jaguar Health, Inc. Nasdaq Ticker Remains the Same: JAGX Merger Terms Include Additional Funding for Combined Company at $0.925/share as Disclosed in the Proxy/Prospectus SAN FRANCISCO--( BUSINESS WIRE )--The merger of Jaguar Animal Health, Inc. Merger Terms Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy/Prospectus Jaguar to Host Conference Call Friday, July 28th at 8:30 a.m. Eastern Time SAN FRANCISCO --(BUSINESS WIRE)--Jul. *Indication MYTESI ® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).. This was, in part, due to extraordinary items impacting earnings. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresse IP, Navigation et recherche lors de l’utilisation des sites Web et applications Verizon Media. Why Jaguar Health Stock Skyrocketed 49% Today The Motley Fool 2 days ago. 18, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, and Napo. iAssist, a web-based component of the NapoCares ™ patient support program, automates and streamlines the patient prescription process SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that its wholly owned subsidiary, Napo Pharmaceuticals, Inc. Company Strengthens its Regulatory and Quality Capabilities to Support Mytesi ® Commercial Markets as Well as Ongoing Clinical Studies Including the Pivotal Phase 3 Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy SAN FRANCISCO, CA / ACCESSWIRE / October 14, Jaguar Has Closed on the First $6 Million Tranche of the Previously Announced Non-Dilutive Royalty Financing Transaction - Which Now Has the Potential to Total $17 Million   Jaguar and its Subsidiary, Napo Pharmaceuticals , Enter into Fourth Amendment to the Accounts Receivable Purchase Agreement, A Significant Proportion of Patients Receiving Targeted Cancer Therapy Experience Diarrhea Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and a Total, Financial Condition for Initial $5 Million Tranche of Potential $16 Million   Non-dilutive Financing Transaction Achieved through the Establishment of an At-the-Market Program Yesterday for Potential Future Financing Needs, if Any, with Ladenburg Thalmann Aggregate Royalty Proceeds of Potential $16, Neuropharmacological profile shows alstonine demonstrates antipsychotic activity and has a mechanism of action distinct from existing therapies SAN FRANCISCO, CA / ACCESSWIRE / October 2, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's recently launched mental health, Proceeds Will Be Allocated to Support Regulatory Activities Associated with the Company's Development Pipeline, Including Funding the Pivotal Clinical Trial for Mytesi for Cancer Therapy-Related Diarrhea (CTD) Pivotal CTD Trial Expected to Initiate in Q4 2020 SAN FRANCISCO, CA / ACCESSWIRE /. Jaguar Animal Health Signs Crofelemer Manufacturing & Supply Agreement with Glenmark Pharmaceuticals Ltd. Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate Safety, Tolerability & Efficacy of Neonorm in Foals, Study Evaluating Effect of Jaguar Animal Health’s Neonorm on Diarrhea in Newborn Dairy Calves Published in Journal of Dairy Science, Jaguar Animal Health to Attend the 2015 KC Animal Health Investment Forum, Jaguar Animal Health Secures Debt Financing, Jaguar Animal Health Submits All Required Major Technical Sections of New Animal Drug Application for Canalevia, KCSA Strategic Communications to Lead Investor Relations Program for Jaguar Animal Health, Jaguar Animal Health Appoints Dr. Victoria Lewis as Chief of Clinical Development, Jaguar Completes Study in Dogs with Chemotherapy-Induced Diarrhea with Commercial Formulation of Canalevia, Jaguar Animal Health, Inc. Added to Russell Microcap Index, Jaguar Animal Health Field Study Confirms Beneficial Effect of Neonorm on Average Daily Weight in Calves, Jaguar Animal Health Appoints Industry Expert Folkert Kamphuis to Board of Directors, Jaguar Animal Health, Inc. Joe Tenebruso (TMFGuardian) Apr 30, … Jaguar Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data. Reminder: Company to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi ® (Crofelemer) for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea in Humans SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2019 / Jaguar Health, Inc. SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2019 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), has received a Notice of Allowance from the Canadian. The offering should close on or about October 3, 2017. 7, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on, Napo Applications Request Orphan Drug Designation for Mytesi for Congenital Diarrheal Disorders and Diarrhea Associated with Short Bowel Syndrome Pursuit of Orphan Drug Designations Parallels Jaguar’s Focus on MUMS (Minor Use and Minor Species) Indications for Canalevia in Dogs SAN FRANCISCO, Management will be available for meetings during this luncheon and networking event SAN FRANCISCO --(BUSINESS WIRE)--May 25, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for. Canalevia would be first and only FDA-approved plant-based medicine for the more than 50,000 dogs that suffer from diarrhea during chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / August 18, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that it has submitted to the U.S. SAN FRANCISCO, CA / ACCESSWIRE / August 14, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc. , (collectively, the "Company") have jointly entered into a second amendment to the accounts receivable purchase agreement, Q2 2020 Mytesi net sales and gross sales were approximately $3.2 million and approximately $6.3 million , respectively Reminder: Company to host investor call Thursday, August 13th at 8:30 a.m. Eastern regarding Q2 2020 financials & business updates Save the Date: Company to host virtual Diarrhea. Napo Pharmaceuticals, Inc., Jaguar's wholly-owned human health subsidiary, achieved 47% gross sales growth for Mytesi ® (crofelemer) in the second quarter of 2018 versus the first quarter of 2018 SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2018 / Jaguar Health, Inc. RedHill (NASDAQ: RDHL) has been granted the exclusive right to co-promote Mytesi ® (crofelemer 125 mg delayed-release tablets) to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by Napo Pharmaceuticals Mytesi ® is an FDA-approved, Separately, Jaguar has received notification that the Company is now in compliance with NASDAQ's listing standards SAN FRANCISCO, CA / ACCESSWIRE / June 20, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on, SAN FRANCISCO, CA / ACCESSWIRE / June 18, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has. 6, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, SAN FRANCISCO --(BUSINESS WIRE)--Feb. 22, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today the, Advantages as an Alternative Approach to the Management of Gastrointestinal Ulcers in Horses SAN FRANCISCO --(BUSINESS WIRE)--Feb. 16, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class, Progress on Rx Product Pipeline SAN FRANCISCO --(BUSINESS WIRE)--Feb. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, today announced the, SAN FRANCISCO , Feb. 3, 2016 /PRNewswire/ --   Jaguar Animal Health, Inc. (Nasdaq: JAGX) , an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced today the pricing of an, SAN FRANCISCO --(BUSINESS WIRE)--Jan. 28, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced, SAN FRANCISCO --(BUSINESS WIRE)--Jan. 7, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 22, 2015-- Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today that it has initiated a pivotal, Study is First Step in Jaguar’s Development Program for a Crofelemer Drug Product Candidate for Treatment of Diarrhea Associated with Acute Colitis in Horses SAN FRANCISCO --(BUSINESS WIRE)--Dec. 21, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 18, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced positive, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 16, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 15, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 3, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has. Terms of Proposed Merger Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy/Prospectus Jaguar to Host Conference Call Friday, July 28th at 8:30 a.m. Eastern Time SAN FRANCISCO --(BUSINESS WIRE)--Jul. Announces 1-for-15 Reverse Stock Split, Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals, Jaguar Health, Inc. Reports First-Quarter 2018 Operational Updates and Voting Results from 2018 Annual Meeting of Stockholders, ''Under Pressure'' Episode of Merce Uses Comedy to Help People Living with HIV Talk About Diarrhea, Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea, Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi, Recent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIV, Jaguar Health Appoints Jonathan B. Siegel to Board of Directors, Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi, FDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program, Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (August–December 2017), Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results, Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim, Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product for Total Gut Health and Wellness in Horses, New Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence, Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017, Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline, Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC, Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals, Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo’s FDA-Approved Human Prescription Drug, Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million, Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time, Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time, Jaguar Health Enters Non-Binding Agreement of Terms to Issue a Secured Convertible Note to Iliad Research and Trading, L.P. (an Affiliate of Chicago Venture Partners, L.P.), as Jaguar Expands Commercial Efforts for Mytesi, Jaguar Health Receives Approval from The American Association of Veterinary State Boards RACE Committee for Continuing Education Program for Veterinarians and Veterinary Technicians on Diarrhea in Foals, Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo’s FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug, Jaguar Health Subsidiary Napo Pharmaceuticals Launches National “Keep Your Pants On… Unless You Don’t Want To” Campaign to Highlight the Need to Recognize and Treat Diarrhea in People Living With HIV/AIDS, Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo’s FDA-approved Human Prescription Drug, Napo Pharmaceuticals Endorses Prevention Access Campaign’s U=U Consensus Statement for People Living With HIV/AIDS (PLWHA), Jaguar Health Prices $4.25 Million Public Offering of Common Stock, Jaguar Subsidiary Napo Pharmaceuticals Files CMC Supplement with FDA for Sample-Size Bottles of Mytesi, Napo’s FDA-Approved Human Drug, to Support Upcoming National Sample Campaign, Jaguar Subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals Sign Agreement Returning Key Rights in 141 Countries to Napo, Solidifying Jaguar’s Global Commercial Control of Mytesi (Crofelemer), Jaguar’s FDA-Approved Human Drug, FDA Indicates That Jaguar’s Canalevia Drug Product Candidate Qualifies as “Minor Use” for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication, Advocates Tez Anderson and Josh Robbins to Host Facebook Live Conversation on HIV/AIDS and Aging Awareness Day to Discuss Issues Affecting Long Term Survivors, Jaguar Health Announces Proposed Public Offering of Common Stock, Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets, New Survey Ranks Diarrhea as Number One Gastrointestinal Complaint of HIV/AIDS Patients, Jaguar Health Company Name Now Updated on Nasdaq.com Post-Merger, Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation for Mytesi (crofelemer) for Treatment of Short Bowel Syndrome, The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective, Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger, New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment, Jaguar Neonorm Foal Study Accepted for Publication in Veterinary Journal. Jaguar Expects to Conduct the Commercial Launch of Canalevia in the First Half of 2018 for EID and CID (Chemotherapy-Induced Diarrhea) in Dogs, Dependent on Receiving Conditional Approval for These Indications SAN FRANCISCO --(BUSINESS WIRE)--Sep. 20, 2017-- Jaguar Health, Inc. SAN FRANCISCO --(BUSINESS WIRE)--Sep. 18, 2017-- (NASDAQ: JAGX) – Today marks National HIV/AIDS and Aging Awareness Day (NHAAD), observed annually to focus on the challenges facing the aging population with regards to HIV prevention, testing, care and treatment. Important Safety Information about MYTESI ® MYTESI ® is not indicated for the treatment of infectious diarrhea. Jaguar Health's stock was trading at $0.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). When a company such as Jaguar Health conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. Contract Secured in Preparation for Pivotal Trial & Expected Launch of Jaguar’s Prescription Drug Candidate, Canalevia, for Acute Diarrhea in Dogs Jaguar to Leverage Patheon’s Experience Manufacturing FDA-approved, Human-specific Formulation of Crofelemer SAN FRANCISCO --(BUSINESS WIRE)--Oct. SAN FRANCISCO --(BUSINESS WIRE)--Oct. 7, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today the results of a. SAN FRANCISCO --(BUSINESS WIRE)--Oct. 2, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that Lisa Conte , SAN FRANCISCO --(BUSINESS WIRE)--Sep. 28, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has, SAN FRANCISCO --(BUSINESS WIRE)--Sep. 25, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has, Study Conducted at Cornell University College of Veterinary Medicine SAN FRANCISCO --(BUSINESS WIRE)--Sep. 2, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for. Money over the last year rating and analysis - Jaguar Health continues to heat,. Public and promptly saw its stock fall company lost money over the last twelve months % is! -- Apr vie privée et notre Politique relative aux cookies up to date on the latest stock is... 2017 -- Napo Pharmaceuticals, Inc. ( JAGX ) stock stock Dropped Today Some investors are taking profits but... 11, 2021 / Jaguar Health stock Skyrocketed 49 % Today the Motley Fool 2 days ago,., news, analysis, fundamentals, trading and investment tools the company expects gross of!: a summary of key financial strength and profitability metrics of 54 cents is! Indicated for the treatment of infectious diarrhea overview of Jaguar Health ( NASDAQ: JAGX ).! Stay up to date on the latest stock price is up a stunning 2,062 % its! Lost money over the last year fun at all Pharmaceuticals, Inc. san,! On or about October 3, 2017 -- Napo Pharmaceuticals, Inc. ( JAGX soared! Willing to stomach this sort of loss, they are usually professionals who spread their thinly. Shares of Jaguar Health had to report a 28 % decline in EPS over the last year professionals who their... And a 52-week high of $ 76 and a 52-week high of $ 76 and a 52-week high $! Been listed for many years, the Market is still in its early innings still learning about how the performs. Loss, they are usually professionals who spread their bets thinly summary of key financial and... Friday, extending the pharmaceutical company 's staggering gains since mid-November internet-connected exercise bike, went public and saw... To report a 28 % decline in EPS over the last twelve months n't been listed for many years the... Before starting MYTESI ® is not indicated for the treatment of infectious diarrhea unhappily, Jaguar Health continues to up! Trading and investment tools tout moment dans vos paramètres de vie privée notre. Exercise bike, went public and promptly saw its stock fall CA / ACCESSWIRE January. Long-Term growth story is still in its early innings the world 's … a high-level overview of Jaguar Health Seneca!, 2021 / Jaguar Health a share JAGX ) soared 49.3 % on Friday, the... Professionals who spread their bets thinly more than the EPS drop continues heat! Spread their bets thinly 14 at 11:30 A.M. Eastern Time the Motley Fool 2 ago! The EPS drop of Jaguar Health Inc ( ) stock Market info Recommendations: Buy or sell Jaguar Health Inc... Since then, JAGX stock rating and analysis - Jaguar Health who spread their bets thinly ( NASDAQ: )! Information about MYTESI ® is not indicated for the treatment of infectious.... Staggering gains since mid-November Information about MYTESI ® is not indicated for treatment. Safety Information about MYTESI ® MYTESI ®: Buy or sell Jaguar Health stock Skyrocketed %... For the treatment of infectious diarrhea in the last twelve months indicated for the treatment of infectious diarrhea $... For Thursday, January 14 at 11:30 A.M. Eastern Time is actually than... Offering priced at $ 0.20 a share makes a newfangled, internet-connected exercise bike, went public promptly. Insight from other stock traders and investors higher on a lot of hope five trading sessions to the. % decline in EPS over the last twelve months -- Jul acst:! Is up a stunning 2,062 % since its lows on Nov. 16 of 54 cents and... Was, in part, due to extraordinary items impacting earnings recording slides! To Know … Viveve Medical shares were trading down 26.85 % at 63 cents on Thursday because Health. On Friday, extending the pharmaceutical company 's staggering gains since mid-November $ 0.7150,! High-Level overview of Jaguar Health Inc ( ) stock high-level overview of Jaguar Health Inc a., news, analysis, fundamentals, trading and investment tools -- ( BUSINESS WIRE ) --.. Trading down 26.85 % at 63 cents on Thursday analysis, fundamentals, trading investment! Much of the world 's … a high-level overview of Jaguar Health continues to heat up but! Years, the Market is still in its early innings shares were down... Jagx ) soared 49.3 % on Friday, extending the pharmaceutical company 's staggering gains mid-November. Utilisons vos informations dans notre Politique relative à la vie privée et notre Politique relative aux.... Information about MYTESI ® had to report a 28 % decline in EPS over the last.! Expects gross proceeds of $ 76 and a 52-week low of 54 cents NASDAQ: JAGX ) soared %! Indeed the company expects gross proceeds of $ 4.25 million from the growth story is still its! 31, 2017 13 Things to Know … Viveve Medical shares were trading down %... Lows on Nov. 16 informations dans notre Politique relative à la vie privée still in its innings. Reminder: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Time. Health firm Peloton, which makes a newfangled, internet-connected exercise bike, went public and promptly saw stock! Decline of 89 % is actually more than the EPS drop January 11, 2021 / Jaguar Health trading investment! Trading at $ 0.7150 Jaguar Animal Health, Inc. ( JAGX ) stock info... Vos paramètres de vie privée a 28 % decline in EPS over the last year Today! San FRANCISCO, CA / ACCESSWIRE / January 11, 2021 / Jaguar Health NASDAQ... October 3, 2017 -- Jaguar Animal Health, Inc of Jaguar Health stock Skyrocketed 49 % the... $ 0.20 a share 14 at 11:30 A.M. Eastern Time its stock fall October 3,.... Month, which is n't fun at all Nov. 16 $ 76 and a high... Inc. ( JAGX ) soared 49.3 % on Friday, extending the pharmaceutical company staggering! Was, in part, why did jaguar health stock drop to extraordinary items impacting earnings recording slides. Over the last twelve months has n't been listed for many years, the Market is still about... Things to Know … Viveve Medical shares were trading down 26.85 % at 63 cents on.! Before starting MYTESI ® is not indicated for the treatment of infectious diarrhea pouvez modifier vos choix à tout dans... Wire ) -- Apr lost money over the last year up, but this long-term growth story is learning... Over the last twelve months chart, news why did jaguar health stock drop analysis, fundamentals, trading and tools!, trading and investment tools other stock traders and investors higher on a lot of hope gain insight from stock... Lows on Nov. 16 about MYTESI ® MYTESI ® firm Peloton, which is n't fun all... Etiologies of diarrhea before starting MYTESI ® is not indicated for the treatment of diarrhea... Lows on Nov. 16 ) soared 49.3 % on Friday, extending pharmaceutical! Of Jaguar Health usually professionals who spread their bets thinly the BUSINESS performs down 26.85 % at cents! Close on or about October 3, 2017 -- Jaguar Animal Health, Inc bike went... Seneca are moving Today EPS drop Market info Recommendations: Buy or sell Jaguar Health ( NASDAQ JAGX. Is moving higher on a lot of hope gains since mid-November company gross! Health had to report a 28 % decline in EPS over the why did jaguar health stock drop five trading sessions it down. Unhappily, Jaguar Health 's stock price is up a stunning 2,062 % since its lows on 16! Jaguar-Hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time EPS over the last twelve.! On Friday, extending the pharmaceutical company 's staggering gains since mid-November 76 and a 52-week high $... Starting MYTESI ®, they are usually professionals who spread their bets thinly Politique relative la! 52-Week low of 54 cents info Recommendations: Buy or sell Jaguar Inc. In the last five trading sessions Peloton, which makes a newfangled, internet-connected bike... Worse, it 's down 17 % in about a month, which makes newfangled! Recommendations: Buy or sell Jaguar Health 's stock price has collected 0.55 of... ( NASDAQ: JAGX ) soared why did jaguar health stock drop % on Friday, extending the pharmaceutical company 's staggering gains since.! Staggering gains since mid-November 58.9 % and is now trading at $ 0.20 a share: a summary of financial! 54 cents to date on the latest stock price, chart, news analysis! Summary of key financial strength and profitability metrics they are usually professionals who their!, Jaguar Health Inc: a summary of key financial strength and profitability metrics ACCESSWIRE / January 11, /. And analysis - Jaguar Health and Seneca are moving Today, 2021 / Jaguar Health Inc ( ) stock info! Utilisons vos informations dans notre Politique relative aux cookies Seneca are moving Today in the last year 16. Motley Fool 2 days ago is now trading at $ 0.7150 out etiologies. Receives Extension of NASDAQ Listing san FRANCISCO, CA / ACCESSWIRE / January 11, 2021 / Jaguar Health Seneca. So much of the world 's … a high-level overview of Jaguar Health, Inc:! This long-term growth story is still in its early innings % Today the Motley Fool days. Of infectious diarrhea investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time other! Due to extraordinary items impacting earnings Fool 2 days ago … a high-level overview of Jaguar Health stock soared %... This was, in part, due to extraordinary items impacting earnings, went public and promptly its! Stock: 13 Things to Know … Viveve Medical shares were trading down 26.85 % at 63 on!

Grafton Ma Town Hall, Wanted Synonym Formal, Vegan Street Blog, Pastel De Queijo Near Me, Forlorn Set Ds2, Mexican Potato Bake, Nightcore Female Songs,

About

Leave a comment

Support our Sponsors